Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.75 |
| ▸ | GPER1 | Q99527 | 3/20 | 0.75 |
| ▸ | GPR183 | P32249 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.58 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.58 |
| ▸ | MASP2 | O00187 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | NSD2 | O96028 | 1/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19911647 | 0.87 | GPER1 (0.58) | L3MBTL1GPER1GPR183NPC1RAB9A | |
| SCHEMBL12700921 | 0.86 | GPER1 (1.00) | L3MBTL1GPER1GPR183NPC1RAB9A | |
| SCHEMBL31006405 | 0.86 | GPER1 (1.00) | L3MBTL1GPER1GPR183NPC1RAB9A | |
| SCHEMBL30657722 | 0.86 | GPER1 (1.00) | L3MBTL1GPER1GPR183NPC1RAB9A | |
| SCHEMBL12700947 | 0.86 | GPER1 (1.00) | L3MBTL1GPER1GPR183NPC1RAB9A | |
| SCHEMBL12524898 | 0.86 | GPER1 (1.00) | L3MBTL1GPER1GPR183NPC1RAB9A | |
| SCHEMBL12700948 | 0.86 | GPER1 (1.00) | L3MBTL1GPER1GPR183NPC1RAB9A | |
| SCHEMBL12700922 | 0.86 | GPER1 (1.00) | L3MBTL1GPER1GPR183NPC1RAB9A | |
| SCHEMBL12700983 | 0.86 | GPER1 (1.00) | L3MBTL1GPER1GPR183NPC1RAB9A | |
| SCHEMBL30569761 | 0.86 | GPER1 (1.00) | L3MBTL1GPER1GPR183NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186936-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | UNM RAINFOREST INNOVATIONS | 2021-06-24 | — | — | US | disclosed |
| US-10682341-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | STC.UNM (US) | 2020-06-16 | — | — | US | disclosed |
| US-10471047-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | STC.UNM (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190160047-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | UNM RAINFOREST INNOVATIONS | 2019-05-30 | — | — | US | disclosed |
| US-20180055826-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | UNM RAINFOREST INNOVATIONS | 2018-03-01 | — | — | US | disclosed |
| WO-2016144647-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | STC.UNM (US) | 2016-09-15 | — | — | WO | disclosed |
| US-8487100-B2 | Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | STC.UNM (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487100-B2 | Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | STC.UNM (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487100-B2 | Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | STC.UNM (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2007019180-A2 | COMPOUNDS FOR BINDING TO ERALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019180-A2 | COMPOUNDS FOR BINDING TO ERALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682341-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | GPER1, NOX4, GPR119 | L3MBTL1 4808/4885GPER1 1/4885GPR183 33/4885 |
| US-20210186936-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | GPER1, NOX4, GPR119 | L3MBTL1 4808/4885GPER1 1/4885GPR183 33/4885 |
| US-20190160047-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | GPER1, NOX4, GPR119 | L3MBTL1 4808/4885GPER1 1/4885GPR183 33/4885 |
| US-20180055826-A1 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | GPER1, NOX4, GPR119 | L3MBTL1 4808/4885GPER1 1/4885GPR183 33/4885 |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | GPER1, ESR2, ESRRG | L3MBTL1 4018/4885GPER1 1/4885GPR183 61/4885 |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | GPER1, ESR2, ESRRG | L3MBTL1 3985/4885GPER1 1/4885GPR183 83/4885 |
| US-10471047-B2 | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity | GPER1, NOX4, GPR119 | L3MBTL1 4808/4885GPER1 1/4885GPR183 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.